论文信息 - Approved biosimilar ranibizumab—a global update - 字舞流文

Approved biosimilar ranibizumab—a global update

A. Loewenstein | B. Kuppermann | M. Kondo | F. Bandello | C. Iwahashi | Ashish Sharma | N. Parachuri | Nilesh Kumar

[1] Ramandeep Singh,et al. A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s Ranibizumab with Lucentis® in patients with neovascular age-related macular degeneration , 2022, Indian journal of ophthalmology.

[2] N. Bressler,et al. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes , 2021, British Journal of Ophthalmology.

[3] M. Naik,et al. Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration , 2021, Clinical Ophthalmology.

[4] P. Kaiser,et al. Efficacy and Safety of Biosimilar FYB201 Compared With Ranibizumab in Neovascular Age-Related Macular Degeneration. , 2021, Ophthalmology.

[5] N. Bressler,et al. Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration , 2020, JAMA ophthalmology.